Pharmaceuticals

Global Molecular Targeted Therapy Industry Trends: Where the Market Is Headed by 2029

November 13, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Molecular Targeted Therapy Market Expected To Become By 2029 Compared With Its 2025 Level?

The molecular targeted therapy market has demonstrated strong expansion in recent years. It is forecast to increase from $65.78 billion in 2024 to $71.64 billion in 2025, at a compound annual growth rate (CAGR) of 8.9%. The market’s historical growth can be linked to the rising occurrence of chronic diseases, a growing need for personalized medicine, the increasing application of biomarkers in drug development, greater adoption of monoclonal antibodies, and an uptick in approvals for oncology therapies.

The molecular targeted therapy market is projected to experience substantial expansion in the coming years. Its size is set to reach $99.4 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period stems from factors such as increased funding in cancer research, a rising need for targeted immunotherapies, the expansion of clinical trial efforts in precision medicine, a greater adoption of companion diagnostics, and improved healthcare availability in developing nations. Key trends expected over this period involve progress in genomic technologies, novel approaches in drug delivery, enhanced spending on research and development, advancements in molecular diagnostics, and the integration of AI solutions for discovering therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

Which Drivers Are Impacting The Molecular Targeted Therapy Market?

The anticipated expansion of the molecular targeted therapy market is linked to the increasing prevalence of personalized medicine. This healthcare approach involves tailoring treatments and preventive measures to an individual’s unique genetic makeup, lifestyle choices, and environmental influences. Its growth is fueled by the growing availability of genetic data, allowing for treatments to be customized to individual genomes, thereby enhancing effectiveness and minimizing adverse reactions. In the context of molecular targeted therapy, personalized medicine provides assistance by examining a patient’s tumor for particular genetic mutations or biomarkers, which then guides the choice of therapies specifically designed to address these irregularities. This method leads to greater treatment accuracy and less damage to healthy cells. As an illustration, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported in February 2024 that the FDA cleared 16 new personalized treatments for individuals with rare diseases in 2023, an increase from six approvals in 2022. Consequently, the expansion of personalized medicine is a key factor propelling the molecular targeted therapy market forward.

What Are The Emerging Segments Gaining Attention In The Molecular Targeted Therapy Market?

The molecular targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy

2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous

3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications

4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors

3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing

4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy

What Are The Latest Industry Trends Transforming The Molecular Targeted Therapy Market?

Key companies within the molecular targeted therapy market are prioritizing the development of advanced products, such as small molecule inhibitors, with the aim of improving patient outcomes across various cancers and chronic conditions. Small molecule inhibitors are minute compounds that can readily permeate cells and hinder specific proteins driving disease progression. For instance, in January 2025, Amgen Inc., a US-based pharmaceutical company, introduced Lumakras (sotorasib) in conjunction with Vectibix (panitumumab), a combination that secured approval from the US Food and Drug Administration (FDA), a US-based government organization. This treatment is intended for adult patients suffering from KRAS G12C-mutated metastatic colorectal cancer who have previously undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as confirmed by an FDA-approved diagnostic. The approval stems from the Phase 3 CodeBreaK 300 trial, which demonstrated that the combined therapy more than doubled progression-free survival compared to the investigated standard of care, marking it as the first targeted therapy to exhibit such a significant benefit in this chemorefractory patient population.

Who Are The Core Companies Influencing The Molecular Targeted Therapy Market Landscape?

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

Which Region Currently Holds The Largest Share Of The Molecular Targeted Therapy Market?

North America was the largest region in the molecular targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Molecular Targeted Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24609&type=smp

Browse Through More Reports Similar to the Global Molecular Targeted Therapy Market 2025, By The Business Research Company

Moist Wound Dressings Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/moist-wound-dressings-global-market-report

Skin Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-care-products-global-market-report

Lip Care Product Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lip-care-product-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795